請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58527完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 簡國龍 | |
| dc.contributor.author | Wei-Chih Liao | en |
| dc.contributor.author | 廖偉智 | zh_TW |
| dc.date.accessioned | 2021-06-16T08:18:35Z | - |
| dc.date.available | 2016-02-15 | |
| dc.date.copyright | 2014-02-25 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-02-10 | |
| dc.identifier.citation | 1. Yadav D, Whitcomb DC. The role of alcohol and smoking in pancreatitis. Nat Rev Gastroenterol Hepatol 2010; 7: 131-45.
2. Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med 2006; 354: 2142-50. 3. Etemad B, Whitcomb DC. Chronic pancreatitis: Diagnosis, classification, and new genetic developments. Gastroenterology 2001; 120: 682-707. 4. Spanier BW, Dijkgraaf MG, Bruno MJ. Trends and forecasts of hospital admissions for acute and chronic pancreatitis in the Netherlands. Eur J Gastroenterol Hepatol 2008; 20: 653-8. 5. CE F. Chronic pancreatitis. In: Feldman M FL, Brandt LJ, ed. Sleisenger & Fordtran's gastrointestinal and liver disease. 9 ed. Philadelphia, PA: W.B. Saunders, 2010:985-1015. 6. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory C, Nickl N. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37: 383-93. 7. Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, Pilotto A, Forlano R. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102: 1781-8. 8. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, Overby CS, Aas J, Ryan ME, Bochna GS, Shaw MJ, Snady HW, Erickson RV, Moore JP, Roel JP. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-34. 9. Attam R, Freeman ML. Endoscopic papillary balloon dilation for stone extraction: if, when, and for how long? Gastrointest Endosc 2010; 72: 1163-6. 10. Baron TH, Harewood GC. Endoscopic balloon dilation of the biliary sphincter compared to endoscopic biliary sphincterotomy for removal of common bile duct stones during ERCP: a metaanalysis of randomized, controlled trials. Am J Gastroenterol 2004; 99: 1455-60. 11. Bergman JJ, Rauws EA, Fockens P, van Berkel AM, Bossuyt PM, Tijssen JG, Tytgat GN, Huibregtse K. Randomised trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bileduct stones. Lancet 1997; 349: 1124-9. 12. Sato H, Kodama T, Takaaki J, Tatsumi Y, Maeda T, Fujita S, Fukui Y, Ogasawara H, Mitsufuji S. Endoscopic papillary balloon dilatation may preserve sphincter of Oddi function after common bile duct stone management: evaluation from the viewpoint of endoscopic manometry. Gut 1997; 41: 541-4. 13. Disario JA, Freeman ML, Bjorkman DJ, Macmathuna P, Petersen BT, Jaffe PE, Morales TG, Hixson LJ, Sherman S, Lehman GA, Jamal MM, Al-Kawas FH, Khandelwal M, Moore JP, Derfus GA, Jamidar PA, Ramirez FC, Ryan ME, Woods KL, Carr-Locke DL, Alder SC. Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones. Gastroenterology 2004; 127: 1291-9. 14. Liao WC, Lee CT, Chang CY, Leung JW, Chen JH, Tsai MC, Lin JT, Wu MS, Wang HP. Randomized trial of 1-minute versus 5-minute endoscopic balloon dilation for extraction of bile duct stones. Gastrointest Endosc 2010; 72: 1154-62. 15. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, Fennerty MB, Ryan ME, Shaw MJ, Lande JD, Pheley AM. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-18. 16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. 17. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29. 18. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189: 1-7. 19. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-77. 20. Li D. Diabetes and pancreatic cancer. Mol Carcinog 2012; 51: 64-74. 21. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-83. 22. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94: 972-80. 23. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-85. 24. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33. 25. AC P. Diabetes Mellitus. In: Longo DL FA, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, ed. Harrison's Principles of Internal Medicine. 18 ed. New York: McGraw-Hill, 2012. 26. Prevention CfDCa. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. 27. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753-9. 28. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293: 194-202. 29. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005; 294: 2872-8. 30. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 2012; 175: 66-73. 31. Sausville EA LD. Principles of Cancer Treatment. In: Longo DL FA, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, ed. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 2012. 32. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903. 33. Choti MA. Adjuvant therapy for pancreatic cancer--the debate continues. N Engl J Med 2004; 350: 1249-51. 34. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13. 35. Twombly R. Adjuvant chemoradiation for pancreatic cancer: few good data, much debate. J Natl Cancer Inst 2008; 100: 1670-1. 36. Abrams RA, Yeo CJ. Combined modality adjuvant therapy for resected periampullary pancreatic and nonpancreatic adenocarcinoma: a review of studies and experience at The Johns Hopkins Hospital, 1991-2003. Surg Oncol Clin N Am 2004; 13: 621-38, ix. 37. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299: 1019-26. 38. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, Pitt HA, Lillemoe KD, Cameron JL. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225: 621-33. 39. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-10. 40. Sutton AJ, Higgins JP. Recent developments in meta-analysis. Stat Med 2008; 27: 625-50. 41. Lefebvre C, Manheimer E, Glanville J. Searching for studies. In: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Chichester: John Wiley & Sons, Ltd, 2008:95-150. 42. Higgins JP, Altman DG. Assessing Risk of Bias in Included Studies. In: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Chichester: John Wiley & Sons, Ltd, 2008:187-241. 43. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53: 1119-29. 44. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535. 45. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA 1992; 268: 240-8. 46. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634. 47. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60. 48. Fletcher J. What is heterogeneity and is it important? BMJ 2007; 334: 94-6. 49. Cochran WG. Some methods of strengthening the common x2 tests. Biometrics 1954; 10: 417-451. 50. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-73. 51. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, Lu G. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006; 24: 1-19. 52. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-24. 53. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, Pham B, Ungar WJ, Einarson TR, Heathcote EJ, Krahn M. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-29. 54. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-58. 55. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992; 135: 1301-9. 56. Shi JQ, Copas JB. Meta-analysis for trend estimation. Stat Med 2004; 23: 3-19. 57. Nicola Orsini RB, Sander Greenland. Generalized least squares for trend estimation of summarized dose–response data. The Stata Journal 2006; 6: 40-57. 58. Aggarwal G, Kamada P, Chari ST. Prevalence of Diabetes Mellitus in Pancreatic Cancer Compared to Common Cancers. Pancreas 2012; 20: 20. 59. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134: 981-7. 60. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 2013; 10: 423-33. 61. GA Wells BS, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 62. Kumaravel B, Bachmann MO, Murray N, Dhatariya K, Fenech M, John WG, Scarpello TJ, Sampson MJ. Use of haemoglobin A1c to detect impaired fasting glucose or Type 2 diabetes in a United Kingdom community based population. Diabetes Res Clin Pract 2012; 96: 211-6. 63. Cryer PE DS. Hypoglycemia. In: Longo DL FA, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, ed. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 2012. 64. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34. 65. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med 2010; 29: 1037-57. 66. White IR. Multivariate random-effects meta-analysis. The Stata Journal 2009; 9: 40-56. 67. Ansary-Moghaddam A, Huxley R, Barzi F, Lawes C, Ohkubo T, Fang X, Jee SH, Woodward M. The effect of modifiable risk factors on pancreatic cancer mortality in populations of the Asia-Pacific region. Cancer Epidemiol Biomarkers Prev 2006; 15: 2435-40. 68. Inoue M, Noda M, Kurahashi N, Iwasaki M, Sasazuki S, Iso H, Tsugane S. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 2009; 18: 240-7. 69. Johansen D, Stocks T, Jonsson H, Lindkvist B, Bjorge T, Concin H, Almquist M, Haggstrom C, Engeland A, Ulmer H, Hallmans G, Selmer R, Nagel G, Tretli S, Stattin P, Manjer J. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev 2010; 19: 2307-17. 70. Grote VA, Rohrmann S, Nieters A, Dossus L, Tjonneland A, Halkjaer J, Overvad K, Fagherazzi G, Boutron-Ruault MC, Morois S, Teucher B, Becker S, Sluik D, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Pala V, Tumino R, Vineis P, Panico S, Rodriguez L, Duell EJ, Molina-Montes E, Dorronsoro M, Huerta JM, Ardanaz E, Jeurnink SM, Beulens JW, Peeters PH, Sund M, Ye W, Lindkvist B, Johansen D, Khaw KT, Wareham N, Allen N, Crowe F, Jenab M, Romieu I, Michaud DS, Riboli E, Romaguera D, Bueno-de-Mesquita HB, Kaaks R. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia; 54: 3037-46. 71. Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, Stampfer MJ, Sato K, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, McTiernan A, Phillips LS, Cochrane BB, Pollak MN, Manson JE, Giovannucci EL, Fuchs CS. Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. Journal of the National Cancer Institute 2013; 105: 1027-1035. 72. Batty GD, Shipley MJ, Marmot M, Smith GD. Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study. Cancer Causes Control 2004; 15: 873-81. 73. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000; 283: 2552-8. 74. Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol 2010; 10: 54. 75. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16. 76. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, van Cutsem E, van Dekken H, Klinkenbijl JH, Jeekel J. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007; 246: 734-40. 77. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101: 908-15. 78. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Buchler MW. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-81. 79. Regel I, Kong B, Raulefs S, Erkan M, Michalski CW, Hartel M, Kleeff J. Energy metabolism and proliferation in pancreatic carcinogenesis. Langenbecks Arch Surg 2012; 397: 507-12. 80. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124: 269-70. 81. Chaika NV, Yu F, Purohit V, Mehla K, Lazenby AJ, DiMaio D, Anderson JM, Yeh JJ, Johnson KR, Hollingsworth MA, Singh PK. Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PLoS One 2012; 7: 7. 82. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40. 83. Sicree R SJ, Zimmet P. The Global Burden. Diabetes and Impaired Glucose Tolerance. IDF Diabetes Atlas. 4 ed: International Diabetes Federation, 2009:1-105. 84. Ma J, Siegel R, Jemal A. Pancreatic Cancer Death Rates by Race Among US Men and Women, 1970-2009. J Natl Cancer Inst 2013; 7: 7. 85. Andersen DK. Diabetes and cancer: placing the association in perspective. Curr Opin Endocrinol Diabetes Obes 2013; 20: 81-6. 86. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50. 87. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med 2002; 346: 393-403. 88. Liao WC, Tu YK, Wu MS, Wang HP, Lin JT, Leung JW, Chien KL. Balloon dilation with adequate duration is safer than sphincterotomy for extracting bile duct stones: a systematic review and meta-analyses. Clin Gastroenterol Hepatol 2012; 10: 1101-9. 89. Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP, Tu YK. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 2013; 14: 1095-103. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58527 | - |
| dc.description.abstract | 背景與目的：關於胰臟炎與胰臟癌有許多廣受爭論的議題。以氣球擴張術或是括約肌切開術治療膽管結石其術後胰臟炎之相對風險仍存有爭議。糖尿病前期是否會增加胰臟癌的風險仍不清楚，胰臟癌腫瘤切除術後應如何治療亦無定論。為解決上述爭議，本論文藉由整合現有證據以比較膽管結石的各種治療及胰臟癌術後各種輔助性治療，及探討空腹血糖值與胰臟癌風險之劑量-反應關係。
方法：文獻回顧找出相關之研究並評估其品質。利用漏斗圖及Egger與Begg試驗評估潛在的小規模研究偏差。以貝氏網絡統合分析比較膽管結石的各種治療及胰臟癌術後各種輔助性治療，以劑量-反應統合分析探討空腹血糖值與胰臟癌風險之劑量-反應關係。 結果：相較於現行標準治療之括約肌切開術，以超過一分鐘之氣球擴張術治療膽管結石其胰臟炎風險相似但總併發症發生率較低，而短於一分鐘之氣球擴張術有較高之胰臟炎風險。空腹血糖值每上升10 mg/dL，胰臟癌之風險會隨之增加13%。輔助性化學治療可減少胰臟癌切除術後死亡率約三分之一，追加放射治療不能進一步延長存活反而會增加副作用。 結論: 氣球擴張術可作為膽管結石之首選治療。糖尿病前期是胰臟癌的危險因子。輔助性化學治療是胰臟癌切除後最佳的治療方式。 | zh_TW |
| dc.description.abstract | Background and aims: Many controversial issues exist regarding pancreatitis and pancreatic cancer. The relative risk of pancreatitis for treating bile duct stones using balloon dilation versus sphincterotomy is under debate. Second, whether prediabetes is a risk factor for pancreatic cancer remains unclear. Third, opinions on the treatment strategy after surgery for pancreatic cancer are widely divided. This dissertation aims to resolve these controversies by synthesizing current evidence to compare various treatments for bile duct stones and available adjuvant therapies for pancreatic cancer, and to evaluate the dose-response relationship between fasting blood glucose and pancreatic cancer risk.
Methods: Eligible studies are identified and assessed for quality. Potential small study bias is evaluated by funnel plots and by tests of Egger and Begg. Bayesian network meta-analysis is used to compare various endoscopic treatments for bile duct stones and adjuvant therapies for pancreatic cancer. The dose-response relation between fasting blood glucose level and risk of pancreatic cancer is evaluated using random-effects linear and non-linear dose-response meta-analysis. Results: Compared with sphincterotomy, treating bile duct stones with balloon dilation for >1 minute has comparable pancreatitis risk and lower overall complications rate, whereas balloon dilation for ≦1 minute has higher pancreatitis risk. The risk of pancreatic cancer rises by 13% per 10 mg/dL increase in fasting blood glucose. Adjuvant chemotherapy reduces mortality by approximately a third compared with observation, whereas additional chemoradiation increases toxicity without further survival benefit. Conclusion: Balloon dilation may be the preferred first-line treatment for bile duct stones. Prediabetes is a risk for pancreatic cancer. Chemotherapy is the optimum adjuvant treatment after resection of pancreatic cancer. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T08:18:35Z (GMT). No. of bitstreams: 1 ntu-103-D98842006-1.pdf: 3124589 bytes, checksum: 6248459d244ae3e589fd76000d8db04d (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | 1. BACKGROUND 1
1.1. PANCREATITIS 1 1.1.1. Epidemiology and significance 1 1.1.2. ERCP as a cause of pancreatitis 2 1.1.3. Balloon dilation vs sphincterotomy and the risk of pancreatitis 2 1.1.4. Knowledge gap-duration of balloon dilation and risk of pancreatitis 3 1.2. PANCREATIC CANCER 4 1.2.1. Epidemiology and significance 4 1.2.2. Diabetes and pancreatic cancer 4 1.2.3. Prediabetes: a potential risk factor for pancreatic cancer 5 1.2.4. KnowIedge gap: dose-response relation between blood glucose and pancreatic cancer 5 1.3. TREATMENT FOR PANCREATIC CANCER 6 1.3.1. Adjuvant therapy for pancreatic cancer 7 1.3.2. Knowledge gap: optimal adjuvant therapy for pancreatic cancer 7 1.4. SYSTEMATIC REVIEW AND META-ANALYSIS 8 1.4.1. Assessing risk of bias in included studies 9 1.4.2. Publication/small study bias 10 1.4.3. Heterogeneity 10 1.4.4. Meta-regression 11 1.4.5. Potential application of meta-analysis in pancreatic diseases 11 1.5. ADVANCED META-ANALYSIS METHODS 12 1.5.1. Network meta-analysis 12 1.5.2. Dose-response meta-analysis 14 2. OBJECTIVE 16 3. METHODS AND RESULTS 17 3.1. RELATIVE SAFETY OF EPBD AND EST AND THE OPTIMAL DURATION FOR EPBD 17 3.1.1. Data sources and searches 17 3.1.2. Study selection 17 3.1.3. Data extraction and quality assessment 18 3.1.4. Data synthesis and analysis 18 3.1.5. Results 19 3.2. DOSE-RESPONSE RELATIONSHIP BETWEEN BLOOD GLUCOSE LEVEL AND PANCREATIC CANCER 22 3.2.1. Search strategy and selection criteria 22 3.2.2. Data extraction and assessment for study quality 23 3.2.3. Data synthesis and analysis 23 3.2.4. Results 25 3.3. OPTIMUM ADJUVANT THERAPY FOR PANCREATIC CANCER 27 3.3.1. Data sources and searches 27 3.3.2. Study selection 28 3.3.3. Data extraction and assessment for risk of bias 28 3.3.4. Data synthesis and analysis 28 3.3.5. Results 30 4. DISCUSSION 33 4.1.1. Relative safety of EPBD and EST and the optimal duration for EPBD 33 4.1.2. Relationship between blood glucose and pancreatic cancer risk 38 4.1.3. Adjuvant treatments for pancreatic cancer 42 5. CONCLUSION 48 6. REFERENCE 50 | |
| dc.language.iso | en | |
| dc.subject | 胰臟炎 | zh_TW |
| dc.subject | 統合分析 | zh_TW |
| dc.subject | 胰臟癌 | zh_TW |
| dc.subject | Pancreatic cancer | en |
| dc.subject | Pancreatitis | en |
| dc.subject | Meta-analysis | en |
| dc.title | 利用先端統合分析方法整合証據以解決胰臟疾病領域之爭議問題 | zh_TW |
| dc.title | Evidence Synthesis using Advanced Meta-analysis Methods for Controversies in Pancreatic Diseases | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-1 | |
| dc.description.degree | 博士 | |
| dc.contributor.coadvisor | 杜裕康 | |
| dc.contributor.oralexamcommittee | 林肇堂,吳明賢,李文宗,林先和,陳杰峰 | |
| dc.subject.keyword | 胰臟癌,胰臟炎,統合分析, | zh_TW |
| dc.subject.keyword | Pancreatic cancer,Pancreatitis,Meta-analysis, | en |
| dc.relation.page | 95 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-02-10 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-103-1.pdf 未授權公開取用 | 3.05 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。